AI Consensus Investment Thesis
Doximity (DOCS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Hold & Monitor
Model signals are balanced; wait for clearer evidence.
1-Year
NEUTRAL$25
+1.9%5-Year
NEUTRAL$42
+66.9%Latest flagship insight
Why This Hidden Digital Healthcare Leader Is Quietly Retiring Its Own Float
There is high consensus that this digital healthcare network operates as a highly defensible physician platform. While temporary regulatory headwinds compress near-term advertising budgets, the primary driver remains an aggressive, self-funded capital return program. The chief risk involves potential workflow disintermediation by native electronic health record systems.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset is undergoing a structural transition from a hyper-growth software narrative to an elite, cash-generative digital utilitydigital utilityA digital service treated like essential infrastructure because users rely on it continuously for core operations.View full glossary entry. Despite near-term top-line deceleration driven by regulatory freezes in pharmaceutical marketing budgets, the core business model remains highly defensible. The company commands authenticated network access to over eighty percent of practicing domestic physicians, establishing an entrenched workflow moat. Operating with zero debt and near-ninety percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, the platform generates exceptional free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, which management is aggressively deploying to retire outstanding equity. This self-funded capital return programcapital return programA planned policy for distributing capital to shareholders through dividends, repurchases, or similar actions.View full glossary entry provides a robust valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry and mathematically compounds per-share earnings power, insulating the asset from macroeconomic and interest rate shocks.
Key insights
- The highly defensible physician network effectnetwork effectA phenomenon where a product gains value as more users join the platform.View full glossary entry secures long-term pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry over pharmaceutical advertisers.
- Aggressive open-market share repurchases systematically shrink the floatfloatThe number of shares available for public trading in the market.View full glossary entry, driving structural per-share value accretion.
- Strategic R&D investments in agentic clinical AI tools defend the workflow interface against emerging competitors.
- Regulatory price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry on pharmaceuticals present a persistent headwind to aggregate marketing budgets.
- The primary structural risk stems from potential native workflow integration by dominant electronic health record providers.
- Sophisticated investors should accumulate during this margin trough, capitalizing on the disconnect between optical GAAP deceleration and underlying cash-flow durability.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The market consensus views the asset as an impaired pandemic-era growth story that has hit a permanent wall. The prevailing narrative focuses heavily on the dramatic deceleration in top-line revenue growth, attributing it to irreversible pharmaceutical budget cuts under new regulatory regimes. Analysts and media outlets fixate on near-term margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry caused by elevated research and development spending on artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry, alongside recent executive turnover. This anchoring bias leads the crowd to classify the company as a mature, low-growth advertising vendor vulnerable to rising interest rates and competitive encroachment, systematically ignoring the underlying cash-flow generation and treating the business model as structurally impaired.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's mischaracterization of the company's business model and capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry strategy. While the crowd sells the stock due to slowing revenue growth and optical margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry, they fail to recognize the durability of its cash conversion. The company operates a highly defensible network on physician attention, boasting near-ninety percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and a forty-nine percent free cash flow marginfcf marginsFree cash flow as a percentage of revenue.View full glossary entry. The elevated research and development spending is not desperate flailing, but a calculated, self-funded moat-building exercise to lock in physicians with free clinical artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry tools. Most critically, the market ignores the mathematics of a ten percent net buyback yield. By aggressively retiring the floatfloatThe number of shares available for public trading in the market.View full glossary entry at a depressed multiple, management is engineering massive per-share earnings compounding that does not rely on top-line hyper-growth.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence catalyst will trigger over the next three to four quarters as the mathematical reality of the massive share repurchase program manifests in per-share metrics. While top-line revenue growth remains in the single digits, the dramatic reduction in the outstanding share count will force a mechanical acceleration in earnings per share. This upward trajectory will be further catalyzed by the stabilization of artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry research and development costs and the initial monetization of high-intent clinical search tools. As consecutive earnings reports demonstrate robust per-share compounding and stable margins, value-oriented institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry will be forced to re-rate the asset from a declining software play to an elite capital-return utility.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
While there is broad agreement that the asset is currently experiencing a period of market capitulation and fear, minor disagreements exist regarding the volatility regime and cycle position. Some perspectives view the asset as already stabilizing at a cyclical troughcyclical troughThe low point in a business or market cycle before potential recovery.View full glossary entry, while others suggest a potential reversal phase or early discovery of its compounding value, reflecting differing horizons on when the massive buyback programbuyback programA corporate authorization to repurchase outstanding shares.View full glossary entry will fully re-rate the equity.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop presents a highly favorable alignment for this asset. In a stagflationary regimestagflationary regimeStagflationary regime is an economic environment combining weak growth, persistent inflation, and pressure on real incomes, margins, and policy flexibility.View full glossary entry characterized by restrictive monetary policy, elevated interest rates, and supply-chain disruptions, capital-intensive and debt-reliant companies face severe headwinds. Conversely, this asset operates as a pristine, purely domestic digital utilitydigital utilityA digital service treated like essential infrastructure because users rely on it continuously for core operations.View full glossary entry with zero corporate debt and exceptional cash generation. It requires virtually no physical capital or external financing, shielding it from refinancing risks and inflationary input costsinput costsCosts of labor, materials, energy, components, transport, and services used to produce or deliver an offering.View full glossary entry. While regulatory pressures on pharmaceutical margins present a mild headwind to advertising budgets, the company's high-ROI digital channel and self-funding buyback engine thrive in a capital-scarce environment, making it an ideal defensive sanctuary.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the long-term viability of the company's artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry transition. Optimistic views assume that the elevated research and development spending is a highly productive, temporary investment that will successfully secure the physician workflow and unlock lucrative enterprise SaaSsoftware as a serviceA software delivery model in which customers access hosted applications, commonly through recurring subscriptions or usage-based charges.View full glossary entry revenues. Conversely, skeptical perspectives argue that the spending represents a defensive, margin-diluting catch-up effort that faces structural obsolescence against native electronic health record systems and frontier models. There is also minor divergence regarding the near-term trajectory of pharmaceutical advertising budgets, with some expecting a rapid post-regulatory normalization and others projecting a prolonged structural contraction.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Aggressive Share Count Reduction | Capital Allocation | +35% | +30% | Management is executing a highly accretive capital return programcapital return programA planned policy for distributing capital to shareholders through dividends, repurchases, or similar actions.View full glossary entry, deploying substantial free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry to retire approximately ten percent of the outstanding floatfloatThe number of shares available for public trading in the market.View full glossary entry annually. In a high-rate macroeconomic environment where capital is expensive, this self-funded share retirement mathematically forces per-share earnings growth and establishes a rigid valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry, independent of near-term top-line revenue fluctuations. |
| Defensible Physician Network Moat | Competitive Positioning | +30% | +20% | The platform commands authenticated network access to over eighty percent of practicing US physicians, creating a powerful digital identity layer with profound network effectsnetwork effectA phenomenon where a product gains value as more users join the platform.View full glossary entry. This structural dominance over clinical attention imposes high switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and grants the company immense pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry over pharmaceutical advertisers and healthcare systems, ensuring highly resilient, recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry streams. |
| Agentic Clinical AI Workflow Integration | Innovation And Product | +20% | +15% | By aggressively front-loading research and development into clinical artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry tools, the company is transitioning from a passive directory to an active workflow operating system. This strategic integration of ambient scribing and clinical search increases daily active user engagement and raises switching barriers, defending the platform against emerging tech competitors. |
| Insulation from Global Macro Headwindsmacro headwindsBroad economic conditions that can slow growth, weaken demand, or pressure asset valuations.View full glossary entry | Macroeconomic And Macrofinancial | +15% | +5.0% | Operating as a debt-free, purely domestic digital business, the company is completely insulated from global trade frictions, supply-chain bottlenecks, and interest rate shocks. This structural resilience makes the asset a premier defensive safe haven for institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry seeking to escape the inflationary and geopolitical pressures currently impacting multinational equities. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Pharma Marketing Budget Compression | Regulatory | -25% | -20% | Regulatory pricing pressures, including federal drug-price negotiations and policy shifts, are compressing pharmaceutical profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry. As drug manufacturers face tighter cash flows, they are rationalizing discretionary marketing budgets, which directly pressures the company's core advertising revenue growth and extends enterprise sales cycles. |
| Top-Line Growth Deceleration | Sector And Industry | -15% | -10% | Having already captured the vast majority of US physicians, the company has saturated its primary user-acquisition curve. Revenue growth has decelerated significantly from historical peaks, forcing a painful transition from a hyper-growth narrative to a mature compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry profile, which triggers mechanical selling by momentum-focused algorithms and growth funds. |
| EHR Incumbent Disintermediation | Competitive Positioning | -12% | -10% | Dominant electronic health record providers are increasingly embedding native clinical communication, telehealth, and artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry tools directly into their core hospital software. This native integration threatens to bypass third-party applications, risking a reduction in physician daily active usage and weakening the company's core advertising value proposition. |
| AI Compute and R&D Margin Drag | Operational Efficiency | -10% | -15% | Deploying and scaling advanced clinical artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry tools requires substantial compute power and elevated research and development spending. This structural step-up in operational costs compresses operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and near-term profitability, acting as a drag on earnings per share until direct monetization of these tools is fully realized. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Native EHR Walled-Garden Lockout | 25% | -35% | Competitive Positioning | Dominant electronic health record providers actively block or restrict third-party API integrations under the guise of cybersecurity or data privacy. This walled-garden approach would increase friction for physicians using the platform during clinical hours, causing daily active usage and advertising views to collapse. |
| Regulatory Ban on Targeted Pharma Ads | 15% | -55% | Regulatory | Federal regulators impose stringent privacy laws or explicit bans on direct-to-physician targeted digital pharmaceutical marketing to reduce healthcare costs. This binary regulatory shift would permanently dismantle the company's primary high-margin cash-flow engine, forcing an immediate and devastating structural repricingstructural repricingA lasting change in market price or valuation caused by a reassessment of long-term fundamentals or risk.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Enterprise SaaSsoftware as a serviceA software delivery model in which customers access hosted applications, commonly through recurring subscriptions or usage-based charges.View full glossary entry Crossover Inflection | 35% | +40% | Innovation And Product | The company successfully transitions its massive free clinical artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry user base into high-margin, recurring enterprise SaaSsoftware as a serviceA software delivery model in which customers access hosted applications, commonly through recurring subscriptions or usage-based charges.View full glossary entry contracts across major health systems. Decoupling revenue from cyclical pharmaceutical advertising budgets would trigger a massive valuation re-rating and accelerate top-line growth. |
| Mega-Cap Tech Acquisition | 20% | +50% | Competitive Positioning | A technology giant seeking immediate, compliant access to the US healthcare system executes a premium buyout to acquire the company's verified physician network. Replicating this network is virtually impossible, making a strategic acquisition highly attractive for hyperscalershyperscalersVery large cloud or internet-platform operators that run computing infrastructure at global scale.View full glossary entry seeking to distribute their own medical AI models. |
Company Financial Analysis
Doximity Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company is currently experiencing a tale of two financial statements. On one hand, sales growth has slowed down significantly from its pandemic-era highs, and net income has dropped due to a big jump in spending on artificial intelligence technology. On the other hand, the company's cash generation remains absolutely spectacular, bringing in a record amount of free cash flow that represents nearly half of its total revenue. The reports strongly agree that this cash-flow engine is incredibly healthy and provides a solid safety net. However, there is a clear disagreement on the future outlook: some believe that sales will quickly bounce back as drug companies return to the platform, while others worry that the slowdown is permanent and that high technology costs will continue to eat into profits. Overall, the massive cash flow is being used to buy back shares, which helps protect investors.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | USD 644.9M | USD 196.1M | USD 317.5M |
| 2025 | USD 570.4M | USD 223.2M | USD 266.7M |
| 2024 | USD 475.4M | USD 147.6M | USD 178.3M |
| 2023 | USD 419.1M | USD 112.8M | USD 173.4M |
| 2022 | USD 343.5M | USD 154.8M | USD 120.9M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 23.2x | TTM | Native | USD / USD |
| 2025 | 51.8x | TTM | Native | USD / USD |
| 2024 | 36.9x | TTM | Native | USD / USD |
| 2023 | 57.5x | Annual | Native | USD / USD |
| 2022 | 71.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's core profitability remains exceptionally strong, highlighted by gross margins near ninety percent, meaning it costs almost nothing to serve each additional user on the platform. However, operating margins have recently shrunk because the company is spending heavily on artificial intelligence and computer power. The reports agree that this margin squeeze is happening, but they clash on what comes next. Some believe this is a temporary dip and that profit margins will bounce back once the new AI tools are fully built and start making money. Others argue that running advanced AI tools is structurally more expensive than running a simple social network, meaning profit margins may never return to their historical highs. Despite this squeeze, the company remains far more profitable than the average business, making its current valuation look highly attractive to cash-focused investors.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | USD 214.9M | 33.3% | 30.4% |
| 2025 | USD 227.8M | 39.9% | 39.1% |
| 2024 | USD 163.9M | 34.5% | 31.0% |
| 2023 | USD 125.1M | 29.9% | 26.9% |
| 2022 | USD 113.5M | 33.0% | 45.1% |
Balance sheet and leverage
The company's balance sheet is an absolute fortress, and there is unanimous agreement across all reports on its incredible safety. The company carries virtually zero debt and holds a massive pile of cash and short-term investments. This means the company faces no risk of running out of money or struggling with high interest rates, which are currently hurting many other tech firms. This financial safety gives management the unique ability to act aggressively while others are playing defense. Specifically, they are using their cash to buy back a massive amount of their own stock, which makes each remaining share more valuable. There is very little disagreement here; the balance sheet completely protects the company from bad economic times and gives it the flexibility to buy up struggling competitors or continue returning cash to its shareholders.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2026 | USD 10.2M | USD 748.6M | USD 209M net cash | 6.09x |
| 2025 | USD 12.4M | USD 915.7M | USD 197.2M net cash | 6.97x |
| 2024 | USD 14.5M | USD 762.9M | USD 82.2M net cash | 6.20x |
| 2023 | USD 15.6M | USD 841M | USD 142.4M net cash | 6.99x |
| 2022 | USD 1.1M | USD 798.1M | USD 111.7M net cash | 8.12x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates an incredibly light business model that requires almost no spending on physical equipment or buildings, which is a huge advantage when costs are rising elsewhere. Instead, the company is focusing its financial power on research and development to build advanced artificial intelligence tools for doctors. The reports agree that this heavy spending is a deliberate move to protect the company's network from competitors. However, opinions differ on what this spending means for the future. Optimistic views see this as a smart, long-term investment that will eventually allow the company to charge hospitals recurring software fees. Skeptical views worry that this is a costly, defensive move that might not bring in new revenue, especially since giant tech companies are spending billions on similar tools. Investors should watch whether these new tools actually help the company grow.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | USD 9M | USD 130.7M |
| 2025 | USD 6.5M | USD 93M |
| 2024 | USD 5.8M | USD 82M |
| 2023 | USD 6.2M | USD 80.2M |
| 2022 | USD 5.7M | USD 62.4M |
Quarterly Forecast Scenarios
Doximity Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $20.55 | $22.59 | $23.61 | $736.09 | |
| $19.73 | $23.28 | $25.03 | $724.14 | |
| $18.74 | $24.37 | $27.50 | $713.57 | |
| $19.11 | $25.47 | $28.90 | $723.38 | |
| $18.16 | $26.09 | $30.06 | $716.61 | |
| $17.07 | $27.03 | $32.19 | $738.34 | |
| $16.39 | $28.06 | $33.80 | $746.91 | |
| $16.88 | $28.99 | $34.46 | $771.93 | |
| $16.37 | $29.48 | $35.84 | $782.73 | |
| $16.04 | $30.53 | $38.35 | $807.31 | |
| $15.56 | $31.92 | $39.50 | $822.72 | |
| $15.72 | $33.10 | $42.66 | $846.10 | |
| $15.09 | $33.87 | $41.38 | $852.53 | |
| $14.79 | $35.07 | $43.45 | $882.91 | |
| $14.34 | $36.40 | $46.16 | $900.46 | |
| $14.63 | $37.03 | $46.54 | $922.67 | |
| $14.05 | $37.80 | $46.32 | $935.91 | |
| $13.77 | $38.74 | $48.64 | $952.30 | |
| $13.35 | $40.26 | $51.78 | $976.28 | |
| $13.09 | $41.71 | $53.85 | $1,002 |
Research Provenance
References & Context
This Doximity consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Sources retained from AI Researcher searches
Showing the top 6 of 6 deduplicated sources retained for this batch.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- 01glass.healthglass.health
- 02seekingalpha.comseekingalpha.com
- 03stocktitan.netstocktitan.net
- 04voiceboxmd.comvoiceboxmd.com
- 05youtube.comyoutube.com
- 06zacks.comzacks.com
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2021-01-01–2026-03-31, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).